{"ATC Code":"N06AX14","Abbreviation":"","Aliases":["66981-73-5","Coaxil","Stablon","Tianeptina","0T493YFU8O","TPI-1062","Jnj-39823277","S-1574","(1)-7-((3-Chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid S,S-dioxide","Tianeptinum"],"Biological Half-Life":"Approximately 2.5 h","CAS":"72797-41-2","ChEBI":"CHEBI:91749","ChEMBL":"CHEMBL1289110","ChemicalClasses":["carboxylic acid"],"Chirality":"unknown","Classes":null,"Drug Indication":"Used primarily in the treatment of major depressive disorder and anxiety. It is currently being studied for fibromyalgia pain treatment.","DrugClasses":["antidepressant","depressant"],"EINECS":"276-851-9","EliminationHalfLife":"2.5 – 3 hours4 – 9 hours (elderly)\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e","European Community (EC) Number":"276-851-9","HMDB ID":"HMDB0042038","HeavyAtomCount":29,"IUPACName":"7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid","InChI":"InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26)","InChIKey":"JICJBGPOMZQUBB-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e25\u003c/sub\u003eClN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e4\u003c/sub\u003eS","MolecularWeight":"437.0 g/mol","Opticalactivity":"( - )","Pharmacodynamics":"Analyses in large-scale epidemiologic surveys have shown that the anxiety disorders are widely comorbid with major depression. This makes antidepressant with anxiolytic properties particularly unique and attractive.  Tianeptine is effective in reducing depressive symptoms in mild to severe major depressive disorder and also alleviates anxious symptoms associated with depression without the need for coadministration of an anti-anxiety medication.     These findings, however, are met with controversial data.  In a study of healthy volunteers, Tianeptine-treated subjects were less accurate at identifying facial expressions, suggesting a lack of improvement in the psychomotor symptoms of depression. The tianeptine group also showed reduced memory and reduced attentional vigilance to various stimuli.","PrevSalts":[],"PubChemId":68870,"Record Description":["Tianeptine is a racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). It has a role as a mu-opioid receptor agonist, a second generation antipsychotic and an anxiolytic drug. It contains a (R)-tianeptine and a (S)-tianeptine.","Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS). Structurally, it is classified as a tricyclic antidepressant (TCA), however, it possesses different pharmacological properties than typical tricyclic antidepressants.  Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s. Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in Asia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S.","TIANEPTINE is a small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.","Tianeptine is a racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). It has a role as a mu-opioid receptor agonist, a second generation antipsychotic and an anxiolytic drug. It contains a (R)-tianeptine and a (S)-tianeptine."],"RefCount":5,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Tianeptine","Name":"Tianeptine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q424260","Name":"Tianeptine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB09289","Name":"Tianeptine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/68870","Name":"Tianeptine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1289110","Name":"Tianeptine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:91749","Name":"Tianeptine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=72797-41-2","Name":"Tianeptine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0042038","Name":"Tianeptine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D02575","Name":"Tianeptine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/XV6773012I","Name":"Tianeptine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID7048295","Name":"Tianeptine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 68870, Tianeptine. Accessed July 3, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/68870\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/68870\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Tianeptine. UNII: XV6773012I. Global Substance Registration System. Accessed July 3, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/XV6773012I\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/XV6773012I\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed July 3, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e","Carlhant D, Le Garrec J, Guedes Y, Salvadori C, Mottier D, Riche C. Pharmacokinetics and bioavailability of tianeptine in the elderly. Drug Investigation. September 1, 1990; 2(3):167–172."],"SMILES":"CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O","Scheduling":[{"gov":"Brazil","ref":["3"],"schedule":"C1 substance"}],"Stereoisomers":["(+)-Tianeptine","(+)-Tianeptine"],"StereoisomersUNII":["",""],"StoreUNII":["0T493YFU8O"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="161.021mm" version="1.2" viewBox="0 0 117.046 161.021" width="117.046mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="162.0" stroke="none" width="118.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="87.324" x2="82.516" y1="156.829" y2="146.798"/>
                  
            <line class="bond" id="mol1bnd2" x1="83.554" x2="90.287" y1="139.579" y2="131.199"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="90.287" x2="104.816" y1="131.199" y2="135.669"/>
                        
                <line x1="92.344" x2="104.189" y1="129.28" y2="132.925"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="104.816" x2="115.992" y1="135.669" y2="125.306"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="115.992" x2="112.537" y1="125.306" y2="110.472"/>
                        
                <line x1="113.296" x2="110.48" y1="124.48" y2="112.391"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="112.537" x2="98.009" y1="110.472" y2="106.002"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="98.009" x2="86.833" y1="106.002" y2="116.365"/>
                        
                <line x1="98.635" x2="89.528" y1="108.746" y2="117.191"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="90.287" x2="86.833" y1="131.199" y2="116.365"/>
                  
            <line class="bond" id="mol1bnd9" x1="86.833" x2="73.117" y1="116.365" y2="109.761"/>
                  
            <line class="bond" id="mol1bnd10" x1="73.117" x2="59.401" y1="109.761" y2="116.365"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="55.946" x2="59.401" y1="131.199" y2="116.365"/>
                        
                <line x1="53.889" x2="56.705" y1="129.28" y2="117.191"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="55.946" x2="63.205" y1="131.199" y2="140.234"/>
                  
            <line class="bond" id="mol1bnd13" x1="77.396" x2="68.413" y1="143.086" y2="143.086"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="63.24" x2="55.71" y1="145.534" y2="149.183"/>
                        
                <line x1="62.177" x2="54.647" y1="143.34" y2="146.988"/>
                      
                <line class="hi" stroke="#C6C62C" x1="63.24" x2="59.475" y1="145.534" y2="147.3585"/>
                <line class="hi" stroke="#FF0D0D" x1="55.71" x2="59.475" y1="149.183" y2="147.3585"/>
                <line class="hi" stroke="#C6C62C" x1="62.177" x2="58.412" y1="143.34" y2="145.164"/>
                <line class="hi" stroke="#FF0D0D" x1="54.647" x2="58.412" y1="146.988" y2="145.164"/>
            </g>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="67.576" x2="69.202" y1="146.696" y2="153.781"/>
                        
                <line x1="65.199" x2="66.826" y1="147.242" y2="154.327"/>
                      
                <line class="hi" stroke="#C6C62C" x1="67.576" x2="68.389" y1="146.696" y2="150.2385"/>
                <line class="hi" stroke="#FF0D0D" x1="69.202" x2="68.389" y1="153.781" y2="150.2385"/>
                <line class="hi" stroke="#C6C62C" x1="65.199" x2="66.01249999999999" y1="147.242" y2="150.78449999999998"/>
                <line class="hi" stroke="#FF0D0D" x1="66.826" x2="66.01249999999999" y1="154.327" y2="150.78449999999998"/>
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="55.946" x2="41.417" y1="131.199" y2="135.669"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="30.241" x2="41.417" y1="125.306" y2="135.669"/>
                        
                <line x1="32.937" x2="42.044" y1="124.48" y2="132.925"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="30.241" x2="33.696" y1="125.306" y2="110.472"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="48.225" x2="33.696" y1="106.002" y2="110.472"/>
                        
                <line x1="47.598" x2="35.753" y1="108.746" y2="112.391"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="59.401" x2="48.225" y1="116.365" y2="106.002"/>
                  
            <line class="bond" id="mol1bnd21" x1="30.241" x2="17.309" y1="125.306" y2="129.266"/>
                  
            <line class="bond" id="mol1bnd22" x1="73.117" x2="73.117" y1="109.761" y2="98.371"/>
                  
            <line class="bond" id="mol1bnd23" x1="69.963" x2="59.918" y1="92.701" y2="86.901"/>
                  
            <line class="bond" id="mol1bnd24" x1="59.918" x2="59.918" y1="86.901" y2="71.661"/>
                  
            <line class="bond" id="mol1bnd25" x1="59.918" x2="46.72" y1="71.661" y2="64.041"/>
                  
            <line class="bond" id="mol1bnd26" x1="46.72" x2="46.72" y1="64.041" y2="48.801"/>
                  
            <line class="bond" id="mol1bnd27" x1="46.72" x2="33.522" y1="48.801" y2="41.181"/>
                  
            <line class="bond" id="mol1bnd28" x1="33.522" x2="33.522" y1="41.181" y2="25.941"/>
                  
            <line class="bond" id="mol1bnd29" x1="33.522" x2="20.324" y1="25.941" y2="18.321"/>
                  
            <g class="bond" id="mol1bnd30">
                        
                <line x1="19.104" x2="19.104" y1="19.025" y2="7.002"/>
                        
                <line x1="21.543" x2="21.543" y1="19.025" y2="7.002"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="19.104" x2="19.104" y1="7.001999999999999" y2="13.013499999999999"/>
                <line class="hi" stroke="#FF0D0D" x1="21.543" x2="21.543" y1="7.001999999999999" y2="13.013499999999999"/>
            </g>
                  
            <line class="bond" id="mol1bnd31" x1="20.324" x2="10.404" y1="18.321" y2="24.048"/>
                  
            <path class="atom" d="M82.677 145.536h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.017 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" fill="#3050F8" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M67.041 144.223q.0 .649 -.476 1.018q-.47 .363 -1.268 .363q-.417 .0 -.768 -.065q-.345 -.06 -.577 -.173v-.589q.244 .113 .607 .202q.369 .089 .762 .089q.548 .0 .827 -.214q.28 -.214 .28 -.577q.0 -.239 -.107 -.399q-.101 -.167 -.351 -.31q-.25 -.143 -.697 -.298q-.625 -.226 -.946 -.553q-.316 -.334 -.316 -.899q.0 -.393 .197 -.667q.202 -.28 .553 -.428q.358 -.155 .816 -.155q.405 -.0 .738 .077q.339 .072 .613 .197l-.196 .529q-.25 -.113 -.548 -.184q-.298 -.077 -.625 -.077q-.458 -.0 -.691 .196q-.232 .196 -.232 .518q.0 .244 .102 .411q.107 .166 .339 .297q.232 .125 .631 .28q.429 .155 .726 .339q.298 .179 .453 .435q.154 .25 .154 .637z" fill="#C6C62C" id="mol1atm12" stroke="none"/>
                  
            <path class="atom" d="M54.041 149.729q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .566 .256 1.328zM50.177 149.729q.0 .922 .387 1.458q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M71.165 157.937q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.245 -.571 -.245 -1.333q.0 -.75 .245 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM67.301 157.937q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M13.213 127.953q-.786 -.0 -1.238 .529q-.452 .524 -.452 1.447q-.0 .911 .416 1.447q.423 .529 1.268 .529q.322 .0 .608 -.053q.291 -.06 .565 -.143v.536q-.274 .101 -.565 .149q-.292 .053 -.697 .053q-.744 .0 -1.25 -.309q-.5 -.31 -.75 -.875q-.25 -.572 -.25 -1.34q-.0 -.744 .268 -1.31q.273 -.565 .803 -.881q.53 -.321 1.28 -.321q.78 -.0 1.352 .286l-.245 .523q-.226 -.101 -.506 -.184q-.273 -.083 -.607 -.083zM15.97 132.376h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm19" stroke="none"/>
                  
            <g class="atom" id="mol1atm20">
                        
                <path d="M75.057 96.971h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.055h.029q-.006 -.108 -.017 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M79.363 96.971h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M22.583 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.757 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.251 -.566 .757 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM18.719 3.078q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .523 -.393 1.452z" id="mol1atm28" stroke="none"/>
                  
            <g class="atom" id="mol1atm29">
                        
                <path d="M9.385 25.938q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 -.0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM5.521 25.938q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M4.305 28.391h-.62v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.62v4.9z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="82.516" x2="84.92" y1="146.798" y2="151.8135"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="83.554" x2="86.9205" y1="139.579" y2="135.389"/>
            <line class="hi" id="mol1bnd12" stroke="#C6C62C" x1="63.205" x2="59.5755" y1="140.234" y2="135.7165"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="77.396" x2="72.9045" y1="143.086" y2="143.086"/>
            <line class="hi" id="mol1bnd13" stroke="#C6C62C" x1="68.413" x2="72.9045" y1="143.086" y2="143.086"/>
            <line class="hi" id="mol1bnd21" stroke="#1FF01F" x1="17.309" x2="23.775" y1="129.266" y2="127.286"/>
            <line class="hi" id="mol1bnd22" stroke="#3050F8" x1="73.117" x2="73.117" y1="98.371" y2="104.066"/>
            <line class="hi" id="mol1bnd22" stroke="#3050F8" x1="73.117" x2="73.117" y1="98.371" y2="104.066"/>
            <line class="hi" id="mol1bnd23" stroke="#3050F8" x1="69.963" x2="64.9405" y1="92.701" y2="89.80099999999999"/>
            <line class="hi" id="mol1bnd31" stroke="#FF0D0D" x1="10.404" x2="15.364" y1="24.048" y2="21.1845"/>
            <line class="hi" id="mol1bnd31" stroke="#FF0D0D" x1="10.404" x2="15.364" y1="24.048" y2="21.1845"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Tianeptine","UNII":"XV6773012I","Wikidata":"Q424260","Wikipedia":"Tianeptine","XLogP":1.2}